Erfonrilimab Biosimilar Bispecific Single-Domain Antibody (PD-L1 × CTLA-4) for Research

Cat No.: GMP-Bios-ab-194

Pre-made Erfonrilimab benchmark antibody (Bispecific Single Domains (VH-VH'-CH), anti-CD274/PD-L1;CTLA4/CTLA-4 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-194-1mg 1mg
GMP-Bios-ab-194-10mg 10mg
GMP-Bios-ab-194-100mg 100mg
GMP-Bios-ab-194-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-made Erfonrilimab biosimilar, Bispecific Single Domains (VH-VH'-CH), Anti-CD274/PD-L1;CTLA4/CTLA-4 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name Erfonrilimab
TargetPD-L1;CTLA-4
FormatBispecific Single Domains (VH-VH'-CH)
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCna;na
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;6rqm:B
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesAlphamab
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Triple-negative breast cancer;Esophageal carcinoma
Conditions Discontinuedna
Development Techna



About target - CD274

1. Protein Programmed cell death 1 ligand 1

2. Gene CD274

3. Organism Homo sapiens (Human)

Function

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410).

As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410).

Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).

The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410).

The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity).

The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).